November 14, 2016

Dramatic Readmission Reductions for CABG, CHF and AMI Attributed to Glytec’s eGlycemic Management System

Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.

Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).

October 11, 2016

Study Conducted at Fred Hutch Shows Transplant Patients Benefit from Glytec’s System for Computer-Guided Glucose Management

Study shows hospitalized transplant patients achieve and sustain improved glucose levels when managed on Glucommander from Glytec.

As a pioneer in technology for glycemic management, Glytec is pleased to share the results of a recent study conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The prospective study, led by Cora Espina Erickson, ARNP, CWCN and published by Bone Marrow Transplantation,1 demonstrates that stringent glucose control among allogeneic hematopoietic cell transplantation (HCT) patients is feasible using Glucommander(TM), the computer-guided glucose management system from Glytec.

October 6, 2016

Glytec Named Fierce Innovation Awards Finalist, Healthcare Edition, for Precision Diabetes Management Solution

The awards competition shines a light on the company’s patented eGlycemic Management System®, or eGMS®.

FierceMarkets, the publisher of FierceHealthcare, FierceHealthIT and FierceHealthPayer, has named Glytec a finalist in the 2016 annual Healthcare Edition of its Fierce Innovation Awards program. One of the primary goals of the program is, ‘To identify and reward the fiercest, most evolutionary technologies and services that can transform healthcare delivery and operational success.’

October 5, 2016

CHI Franciscan Updating Glucose Management Tools, Seeking Robust EHR Integration

CHI Franciscan Health is preparing to implement a new SaaS-based glucose management system that offers proprietary insulin dosing algorithms, analytics and reporting, automated surveillance and alerting, but the real selling point was more seamless EHR integration.

The perceived value of medical devices and ancillary software systems is increasingly tied to how seamlessly they integrate with EHR platforms from Epic or Cerner. That was the case when CHI Franciscan Health in Tacoma, Wash., recently evaluated glucose management systems. One key reason the eight-hospital system chose to implement Glytec’s eGlycemic Management System (eGMS) was its robust integration with Epic.

October 4, 2016

Study Published by Journal of Diabetes Science and Technology Demonstrates Glytec’s Superiority in Meeting ADA Guidelines

Better patient outcomes point to use of a fully automated insulin dosing decision support system as the new standard of care for basal-bolus therapy.

A study published in the Journal of Diabetes Science and Technology (JDST) provides further evidence that Glytec’s patented eGlycemic Management System® (eGMS®) is safer and more effective than traditional approaches to managing basal-bolus therapy. With some 40% of hospitalized patients receiving insulin therapy during their stay, the consequences of inadequate and imprecise dosing — including increased risk of complications and mortality, longer lengths of stay, and higher readmission rates — pose significant cost and quality improvement opportunities for hospitals.

September 30, 2016

Hawaii Pacific Health Receives 2016 HIMSS Enterprise Davies Award Based in Part on Success With Glytec’s eGMS®

Our client, Hawaii Pacific Health, was named a HIMSS Enterprise Davies Award recipient based in part on its success implementing Glytec’s eGlycemic Management System® to support computer-based insulin dosing and a new hypoglycemia protocol.

The results were better glucose control with computer-directed insulin dosing system versus usual care. 39.8% of all glucose values in the ICU setting were above the recommended limit (glucose 180 mg/dl) with usual care. With computer-directed insulin dosing system for intravenous insulin, the hyperglycemia rate was much lower representing just 16.6% of all glucose values.

September 27, 2016

Glytec Receives Three Additional Patent Notices of Allowance from USPTO for its Breakthrough Diabetes Technologies

The notices further validate Glytec’s position as a leader in advanced technologies and innovations for glycemic management.

The company is aggressively building a patent portfolio that affords protection of its proprietary diabetes technologies. The three new allowances will issue as patents over the next 60 days — adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 — bringing the total number of patents held by Glytec to five. The company has more than 30 other U.S. and international patent applications pending.

September 22, 2016

CHI Franciscan Health Selects Glytec’s eGMS® for Precision Diabetes Management

The eGMS® solution suite includes real-time insulin dosing, robust analytics and reporting, automated surveillance and alerting, clinical transformation services, and more.

CHI Franciscan Health of Tacoma, Washington has recently turned to Glytec for its comprehensive eGlycemic Management System®, or eGMS®, which includes FDA-cleared technology for both intravenous and subcutaneous real-time insulin dosing.

September 13, 2016

Palmetto Health to Use Glytec’s eGlycemic Management System® for Diabetes Care

The FDA-cleared technology solution will help facilitate best practices for glycemic management across the integrated health care system.

Palmetto Health, the largest integrated health care system in the South Carolina Midlands region, has selected Glytec’s eGlycemic Management System®, or eGMS®, to support quality of care for patients with diabetes. The cloud-hosted eGMS® software-as-a-service (SaaS) solution will be used enterprise-wide, across all of Palmetto Health’s clinical disciplines.

July 8, 2016

Reduced Inpatient Hypoglycemia With Electronic Glycemic Management System

An electronic glycemic management system (eGMS) may help lower rates of hypoglycemia and lower average blood glucose levels in hospitalized patients compared with usual care, according to a new study.

The aim of this study was to compare hypoglycemia rates in patients managed with an eGMS compared with patients managed by usual care. In this current study, there were 45,335 patients treated with usual care and 13,351 patients treated with eGMS. The target blood glucose was pegged at 100 mg/dL to 180 mg/dL. The researchers evaluated how many patients experiencing mild to moderate hypoglycemia (<70 mg/dL, <60 mg/dL, and <50 mg/dL) and severe hypoglycemia (<40 mg/dL) in the eGMS group compared with the usual care group.

July 2, 2016

Electronics Said to Reduce Hypoglycemic Events

New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.

In an interview, Joseph Aloi, MD, section chief of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, told Diabetes in Control that, “Patients who were treated with the [electronic glycemic management system] had a statistically lower incidence of hypoglycemic events and lower average blood glucose compared with [usual care], suggesting it may be easier to achieve glycemic targets safely for patients in the hospital setting.

June 16, 2016

Electronic Glycemic Management System Reduces Hypoglycemic Event Rate

Hypoglycemic events are less likely in inpatients with diabetes treated with an electronic glycemic management system compared with usual care, according to data presented here.

“Patients who were treated with the [electronic glycemic management system] had a statistically lower incidence of hypoglycemic events and lower average blood glucose compared with [usual care], suggesting it may be easier to achieve glycemic targets safely for patient in the hospital setting,” Joseph Aloi, MD, section chief of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, told Endocrine Today.

Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.

June 5, 2016

Glucommander Linked to Improved Blood Glucose Levels

The inclusion of a computer-guided program (Glucommander) as a component of diabetic ketoacidosis management was associated with significantly less hypoglycemia and faster time to normalization of blood glucose and bicarbonate than standard treatment of diabetic ketoacidosis, according to a new retrospective multicenter study.

The data were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress. The study also demonstrated a significant difference in length of hospital stay for patients treated with Glucommander compared with standard protocol (3.2 vs 4.5 days).

June 1, 2016

Glytec Presents Key Studies at the AACE 25th Annual Scientific and Clinical Congress

Experts demonstrate the ability of automated glucose management to significantly reduce rates of hypoglycemia and DKA.

Glytec, the pioneer and leader in providing innovative, FDA cleared glucose management software solutions, today announced that two abstracts addressing the approach to care for patients suffering from hypoglycemia and diabetic ketoacidosis (DKA) were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress, held from May 25-29th in Orlando, Florida.

May 31, 2016

Computer Algorithms Managing Insulin Dosages Result in Better Glycemic Control

When insulin dosages are calculated using computer algorithms to reach target blood glucose levels, hospitalized patients are less likely to have episodes of low blood sugar and recover sooner from diabetic ketoacidosis than when insulin dosages are calculated without an algorithm.

Those were key findings from two multisite studies presented at the American Association of Clinical Endocrinologists meeting, held May 25-29 in Orlando, Florida. “Computer algorithms facilitate doing the right thing,” said Dr. Joseph A. Aloi, professor of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and the studies’ principal investigator.

March 16, 2016

Nationally-Recognized Riverside Medical Center Selects Glytec as Part of its Ongoing Commitment to Clinical Excellence

Hospital to leverage Glytec’s eGMS ®solution for advanced glycemic management decision support.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, announced today that Riverside Medical Center (RMC), has selected the company’s eGlycemic Management System® (eGMS®) to further strengthen its Diabetes Management Program. eGMS® enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

October 20, 2015

Hartford HealthCare Selects Glytec’s eGMS® for Diabetes Management

Hartford HealthCare will deploy the company’s eGlycemic Management System® (eGMS®) across its five hospitals.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announced today that Hartford HealthCare will deploy the company’s eGlycemic Management System® (eGMS®) across its five hospitals. eGMS® enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

June 8, 2015

Glytec Presents Several Research Studies at the ADA 75th Scientific Sessions

Data continue to validate the benefits of standardized glycemic management through computerized decision support for both IV and subcutaneous insulin dosing.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the American Diabetes Association 75th Scientific Sessions. The 75th Scientific Sessions, taking place from June 5-9th in Boston, are the premier venue for exchanging news and showcasing innovation to the diabetes community.

June 4, 2015

37 More Hospitals Elect to Strengthen Their Diabetes Management Programs with Glytec

Company continues dramatic growth driven by its unprecedented, proven results.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announces 13 additional health systems across the U.S. have recently selected the company’s eGlycemic Management System® (eGMS®). Collectively, they represent 37 new hospital implementations. eGMS® enables providers, payers, and patients to control glucose levels, and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.